The matrikine PGP as a potential biomarker in COPD

The lack of a well-characterized biomarker for the diagnosis of chronic obstructive pulmonary disease (COPD) has increased interest toward finding one, because this would provide potential insight into disease pathogenesis and progression. Since persistent neutrophilia is an important hallmark in CO...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology. Lung cellular and molecular physiology 2015-06, Vol.308 (11), p.L1095-L1101
Main Authors: Abdul Roda, Mojtaba, Fernstrand, Amanda M, Redegeld, Frank A, Blalock, J Edwin, Gaggar, Amit, Folkerts, Gert
Format: Article
Language:English
Subjects:
Animals
Biomarkers
Biomarkers - metabolism
Call for Papers
Cells
Chemokines - metabolism
Chronic obstructive pulmonary disease
Extracellular Matrix - metabolism
Humans
Leukotriene A4 - metabolism
Medical diagnosis
Neutrophils - immunology
Oligopeptides - metabolism
Pathogenesis
Proline - analogs & derivatives
Proline - metabolism
Pulmonary Disease, Chronic Obstructive - diagnosis
Pulmonary Disease, Chronic Obstructive - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The lack of a well-characterized biomarker for the diagnosis of chronic obstructive pulmonary disease (COPD) has increased interest toward finding one, because this would provide potential insight into disease pathogenesis and progression. Since persistent neutrophilia is an important hallmark in COPD Pro-Gly-Pro (PGP), an extracellular matrix-derived neutrophil chemoattractant, has been suggested to be a potential biomarker in COPD. The purpose of this review is to critically examine both biological and clinical data related to the role of PGP in COPD, with particular focus on its role as a clinical biomarker and potential therapeutic target in disease. The data provided in this review will offer insight into the potential use of PGP as end point for future clinical studies in COPD lung disease. Following PGP levels during disease might serve as a guide for the progression of lung disorders.
ISSN:1040-0605
1522-1504
DOI:10.1152/ajplung.00040.2015